ABSTRACT
RhoA and its downstream effector ROCK mediate stress fiber formation and cell contraction through their effects on the phosphorylation of myosin light chain (MLC). Inhibition of the RhoA/ROCK pathway has proven to be a promising strategy for several indications such as cardiovascular disease, glaucoma, and inflammatory disease. In 2010, our group reported urea-based ROCK inhibitors as potential antiglaucoma agents. These compounds showed potent IC50 values in enzymatic and cell-based assays and significant intraocular pressure (IOP)-lowering effects in rats (â¼7 mmHg). (22) To develop more advanced ROCK inhibitors targeting various potential applications (such as myocardial infarction, erectile dysfunction, multiple sclerosis, etc.) in addition to glaucoma, a thorough SAR for this urea-based scaffold was studied. The detailed optimization process, counter-screening, and in vitro and in vivo DMPK studies are discussed. Potent and selective ROCK inhibitors with various in vivo pharmacokinetic properties were discovered.
Subject(s)
Protein Kinase Inhibitors/chemical synthesis , Protein Kinase Inhibitors/pharmacology , Urea/chemical synthesis , Urea/pharmacology , rho-Associated Kinases/antagonists & inhibitors , Adenosine Triphosphate/metabolism , Animals , Cell Line , Chemistry Techniques, Synthetic , Humans , Inhibitory Concentration 50 , Molecular Docking Simulation , Protein Conformation , Protein Kinase Inhibitors/metabolism , Protein Kinase Inhibitors/pharmacokinetics , Rats , Structure-Activity Relationship , Substrate Specificity , Urea/metabolism , Urea/pharmacokinetics , rho-Associated Kinases/chemistry , rho-Associated Kinases/metabolismABSTRACT
SAR and lead optimization studies for Rock inhibitors based on amino acid-derived quinazolines are described. Studies demonstrated that these amino acid derived quinazolinones were mainly pan-Rock (I & II) inhibitors. While selectivity against other kinases could be achieved, selectivity for most of these compounds against PKA was not achieved. This is distinct from Rock inhibitors based on non-amino acid derived quinazolinones, where high selectivity against PKA could be obtained.(22) The inhibitors presented here in some cases possessed sub-nanomolar inhibition of Rock, nanomolar potency in ppMLC cell based assays, low to fair cytochrome P-450 inhibition, and good human microsomal stability.
Subject(s)
Amino Acids/chemistry , Cyclic AMP-Dependent Protein Kinases/antagonists & inhibitors , Quinazolines/chemistry , rho-Associated Kinases/antagonists & inhibitors , Binding Sites , Cyclic AMP-Dependent Protein Kinases/metabolism , Humans , Microsomes/metabolism , Molecular Docking Simulation , Protein Binding , Protein Kinase Inhibitors/chemical synthesis , Protein Kinase Inhibitors/chemistry , Protein Kinase Inhibitors/metabolism , Protein Structure, Tertiary , Quinazolines/chemical synthesis , Quinazolines/metabolism , Structure-Activity Relationship , rho-Associated Kinases/metabolismABSTRACT
Therapeutic interventions with Rho kinase (ROCK) inhibitors may effectively treat several disorders such as hypertension, stroke, cancer, and glaucoma. Herein we disclose the optimization and biological evaluation of potent novel ROCK inhibitors based on substituted indole and 7-azaindole core scaffolds. Substitutions on the indole C3 position and on the indole NH and/or amide NH positions all yielded potent and selective ROCK inhibitors (25, 42, and 50). Improvement of aqueous solubility and tailoring of in vitro and in vivo DMPK properties could be achieved through these substitutions.
Subject(s)
Drug Discovery , Indoles/chemical synthesis , Water/chemistry , rho-Associated Kinases/antagonists & inhibitors , Animals , Binding Sites , Cytochrome P-450 Enzyme Inhibitors , Enzyme Activation/drug effects , Humans , Indoles/chemistry , Indoles/pharmacology , Inhibitory Concentration 50 , Models, Molecular , Molecular Structure , Rats , SolubilityABSTRACT
Rho kinase (ROCK) inhibitors are potential therapeutic agents to treat disorders such as hypertension, multiple sclerosis, cancers, and glaucoma. Here, we disclose the synthesis, optimization, biological evaluation of potent indole and 7-azaindole based ROCK inhibitors that have high potency on ROCK (IC(50)=1 nM) with 740-fold selectivity over PKA (47). Moreover, 47 showed very good DMPK properties making it a good candidate for further development. Finally, docking studies with a homology model of ROCK-II were performed to rationalize the binding mode of these compounds and showed the compounds bound in both orientations to take advantage to H-bonds with Lys-121 of ROCK-II.
Subject(s)
Drug Discovery , Indoles/chemical synthesis , rho-Associated Kinases/antagonists & inhibitors , Binding Sites , Cytochrome P-450 Enzyme Inhibitors , Enzyme Activation/drug effects , Enzyme Inhibitors/chemical synthesis , Enzyme Inhibitors/chemistry , Enzyme Inhibitors/pharmacology , Humans , Indoles/chemistry , Indoles/pharmacology , Inhibitory Concentration 50 , Models, Molecular , Molecular StructureABSTRACT
Rho kinase (ROCK) is an attractive therapeutic target for various diseases including glaucoma, hypertension, and spinal cord injury. Herein, we report the development of a series of ROCK-II inhibitors based on 4-quinazolinone and quinazoline scaffolds. SAR studies at three positions of the quinazoline core led to the identification of analogs with high potency against ROCK-II and good selectivity over protein kinase A (PKA).
Subject(s)
Protein Kinase Inhibitors/chemical synthesis , Protein Kinase Inhibitors/pharmacology , Quinazolinones/chemical synthesis , Quinazolinones/pharmacology , rho-Associated Kinases/antagonists & inhibitors , Protein Kinase Inhibitors/chemistry , Quinazolinones/chemistry , Structure-Activity RelationshipABSTRACT
Rho kinase (ROCK) is a promising drug target for the treatment of many diseases including hypertension, multiple sclerosis, cancer, and glaucoma. The structure-activity relationships (SAR) around a series of tetrahydroisoquinolines were evaluated utilizing biochemical and cell-based assays to measure ROCK inhibition. These novel ROCK inhibitors possess high potency, high selectivity, and appropriate pharmacokinetic properties for glaucoma applications. The lead compound, 35, had subnanomolar potency in enzyme ROCK-II assays as well as excellent cell-based potency (IC(50) = 51 nM). In a kinase panel profiling, 35 had an off-target hit rate of only 1.6% against 442 kinases. Pharmacology studies showed that compound 35 was efficacious in reducing intraocular pressure (IOP) in rats with reasonably long duration of action. These results suggest that compound 35 may serve as a promising agent for further development in the treatment of glaucoma.
Subject(s)
Antihypertensive Agents/chemical synthesis , Isoquinolines/chemical synthesis , Pyrazoles/chemical synthesis , Tetrahydroisoquinolines/chemical synthesis , rho-Associated Kinases/antagonists & inhibitors , Animals , Antihypertensive Agents/pharmacokinetics , Antihypertensive Agents/pharmacology , Cell Line , Humans , In Vitro Techniques , Intraocular Pressure/drug effects , Isoquinolines/pharmacokinetics , Isoquinolines/pharmacology , Microsomes, Liver/metabolism , Models, Molecular , Pyrazoles/pharmacokinetics , Pyrazoles/pharmacology , Rats , Stereoisomerism , Structure-Activity Relationship , Tetrahydroisoquinolines/pharmacokinetics , Tetrahydroisoquinolines/pharmacologyABSTRACT
Rho Kinase (ROCK) is a serine/threonine kinase whose inhibition could prove beneficial in numerous therapeutic areas. We have developed a promising class of ATP-competitive inhibitors based upon a benzimidazole scaffold, which show excellent potency toward ROCK (IC(50)<10nM). This report details the optimization of selectivity for ROCK over other related kinases such as Protein kinase A (PKA).
Subject(s)
Benzimidazoles/pharmacology , Protein Kinase Inhibitors/pharmacology , rho-Associated Kinases/antagonists & inhibitors , Protein Kinase Inhibitors/chemistryABSTRACT
A series of urea-based Rho kinase (ROCK) inhibitors were designed and evaluated. The discovered compounds had excellent enzyme and cellular potency, high kinase selectivity, high aqueous solubility, good porcine corneal penetration, and appropriate DMPK profiles for topical applications as antiglaucoma therapeutics.
ABSTRACT
A series of benzothiazole derivatives as ROCK inhibitors have been discovered. Compounds with good biochemical and cellular potency, and sufficient kinase selectivity have been identified.
Subject(s)
Benzothiazoles/pharmacology , Protein Kinase Inhibitors/pharmacology , rho-Associated Kinases/antagonists & inhibitors , Benzothiazoles/chemical synthesis , Benzothiazoles/chemistry , Drug Design , Molecular Structure , Protein Kinase Inhibitors/chemical synthesis , Protein Kinase Inhibitors/chemistry , Stereoisomerism , Structure-Activity RelationshipABSTRACT
Advances in genomics and proteomics have generated the needs for the efficient identification of key residues for structure and function of target proteins. Here we report the utilization of a new residue-screening approach, which combines a mammalian high-throughput transient expression system with a PCR-based expression cassette, for the study of the post-translational modification. Applying this approach results in a quick identification of essential N-glycosylation sites of a heavily glycosylated neuroglycoprotein Lingo-1, which are sufficient for the support of its surface expression. These key N-glycosylated sites uniquely locate on the concave surface of the elongated arc-shape structure of the leucine-rich repeat domain. The swift residue-screening approach may provide a new strategy for structural and functional analysis.
Subject(s)
Asparagine/analysis , Cell Membrane/metabolism , Membrane Proteins/chemistry , Membrane Proteins/metabolism , Nerve Tissue Proteins/chemistry , Nerve Tissue Proteins/metabolism , Sequence Analysis, Protein/methods , Antigens, Surface/metabolism , Asparagine/metabolism , Cells, Cultured , Glycoproteins/chemistry , Glycoproteins/metabolism , Glycosylation , Humans , Membrane Proteins/genetics , Models, Biological , Mutagenesis, Site-Directed/methods , Nerve Tissue Proteins/genetics , Plasmids/chemistry , Polymerase Chain Reaction/methods , Protein Conformation , Time FactorsABSTRACT
Inhibitors of Rho kinase have been developed based on two distinct scaffolds, benzimidazoles, and benzoxazoles. SAR studies and efforts to optimize the initial lead compounds are described. Novel selective inhibitors of ROCK-II with excellent potency in both enzyme and cell-based assays were obtained. These inhibitors possess good microsomal stability, low cytochrome P-450 inhibitions and good oral bioavailability.
Subject(s)
Benzimidazoles/pharmacology , Benzoxazoles/pharmacology , Chemistry, Pharmaceutical/methods , rho-Associated Kinases/antagonists & inhibitors , Benzimidazoles/chemistry , Benzoxazoles/chemistry , Chromans/chemistry , Drug Design , Glaucoma/drug therapy , Humans , Hypertension/drug therapy , Inhibitory Concentration 50 , Microsomes/drug effects , Microsomes, Liver/metabolism , Models, Chemical , Pyrazoles/chemistry , Pyrimidines/chemistry , rho-Associated Kinases/chemistry , rho-Associated Kinases/metabolismABSTRACT
Secreted Frizzled-related protein-1 (sFRP-1) belongs to a class of extracellular antagonists that modulate Wnt signaling pathways by preventing ligand-receptor interactions among Wnts and Frizzled membrane receptor complexes. sFRP-1 and Wnts are heparin-binding proteins, and their interaction can be stabilized by heparin in vitro. Here we report that heparin can specifically enhance recombinant sFRP-1 accumulation in a cell type-specific manner. The effect requires O-sulfation in heparin, and involves fibroblast growth factor-2 as well as fibroblast growth factor receptor-1. Interestingly, further investigation uncovers that heparin can also affect the post-translational modification of sFRP-1. We demonstrate that sFRP-1 is post-translationally modified by tyrosine sulfation at tyrosines 34 and 36, which is inhibited by the treatment of heparin. The results suggest that accumulation of sFRP-1 induced by heparin is in part due to the relative stabilization of unsulfated sFRP-1 and the direct stabilization by heparin. The study has revealed a multifaceted regulation on sFRP-1 protein by heparin.
Subject(s)
Anticoagulants/pharmacology , Heparin/pharmacology , Protein Processing, Post-Translational/physiology , Proteins/metabolism , Signal Transduction/physiology , Wnt Proteins/metabolism , Cell Line , Fibroblast Growth Factor 2/metabolism , Humans , Intracellular Signaling Peptides and Proteins , Multiprotein Complexes/genetics , Multiprotein Complexes/metabolism , Protein Processing, Post-Translational/drug effects , Proteins/genetics , Proteins/pharmacology , Receptor, Fibroblast Growth Factor, Type 1/metabolism , Recombinant Proteins/genetics , Recombinant Proteins/metabolism , Recombinant Proteins/pharmacology , Signal Transduction/drug effectsABSTRACT
NIMA (never in mitosis arrest)-related kinase 2 (Nek2) is a serine/threonine kinase required for centrosome splitting and bipolar spindle formation during mitosis. Currently, two in vitro kinase assays are commercially available: (i) a radioactive assay from Upstate Biotechnology and (ii) a nonradioactive fluorescence resonance energy transfer (FRET) assay from Invitrogen. However, due to several limitations such as radioactive waste management and lower sensitivity, a need for more robust nonradioactive assays would be ideal. Accordingly, we have developed four quantitative and sensitive nonradioactive Nek2 in vitro kinase assays: (i) a dissociation-enhanced lanthanide fluorescence immunoassay (DELFIA) using peptides identified from a physiologically relevant protein substrate, (ii) DELFIA using Nek2 itself, (iii) a homogeneous time-resolved FRET assay termed LANCE, and (iv) A method of detecting phosphorylated products by HPLC. The DELFIA and LANCE assays are robust in that they generated more than 10-fold and 20-fold increases in signal-to-noise ratios, respectively, and are amenable to robotic high-throughput screening platforms. Validation of all four assays was confirmed by identifying a panel of small molecule ATP competitive inhibitors from an internal corporate library. The most potent compounds consistently demonstrated less than 100 nM activity regardless of the assay format and therefore were complementary. In summary, the Nek2 in vitro time-resolved FRET kinase assays reported are sensitive, quantitative, reproducible and amenable to high-throughput screening with improved waste management over radioactive assays.
Subject(s)
Chromatography, High Pressure Liquid/methods , Fluoroimmunoassay/methods , Protein Serine-Threonine Kinases/analysis , Animals , Antibodies, Monoclonal , Autoantigens/metabolism , Cell Cycle Proteins/metabolism , Europium , Fluorescence Resonance Energy Transfer , Humans , Mice , NIMA-Related Kinases , Peptides/metabolism , Protein Serine-Threonine Kinases/antagonists & inhibitors , Rabbits , Sensitivity and SpecificityABSTRACT
The SHAPES strategy combines nuclear magnetic resonance (NMR) screening of a library of small drug-like molecules with a variety of complementary methods, such as virtual screening, high throughput enzymatic assays, combinatorial chemistry, X-ray crystallography, and molecular modeling, in a directed search for new medicinal chemistry leads. In the past few years, the SHAPES strategy has found widespread utility in pharmaceutical research. To illustrate a variety of different implementations of the method, we will focus in this review on recent applications of the SHAPES strategy in several drug discovery programs at Vertex Pharmaceuticals.
